Phase 4 Psoriatic Arthritis Trial, Recruiting NCT07087912 Sponsor: University of Sao Paulo General Hospital Condition: Psoriatic Arthritis
Back to Psoriatic Arthritis

Phase 4 Psoriatic Arthritis Trial, Recruiting

NCT07087912
Recruiting Phase 4

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are between 12 and 59 years old
  • You are male or female
  • You have been diagnosed with an autoimmune rheumatic disease (such as rheumatoid arthritis, lupus, juvenile idiopathic arthritis, Sjögren's syndrome, or vasculitis) based on recognised medical standards
  • Your autoimmune condition has been stable for at least 3 months
  • You are either taking no immunosuppressive (immune-lowering) medications, or only low-level ones such as hydroxychloroquine, sulfasalazine, low-dose prednisone, methotrexate, leflunomide, azathioprine, or certain combinations of these (confirm with trial site for exact doses)
  • You are a healthy volunteer matched by age and sex to a patient in the trial, with no history of autoimmune or long-term infectious diseases and not taking immune-lowering medications
  • You are willing and able to follow the study procedures and attend follow-up visits
  • If you are a woman who could become pregnant, you have a negative pregnancy test at the start of the study
  • If you are a woman who could become pregnant, you agree to use effective contraception for at least 90 days after receiving the vaccination

Who may not be able to join:

  • You have previously received any dengue vaccine
  • You received a live attenuated vaccine (such as certain flu or MMR vaccines) within the past 4 weeks
  • You received an inactivated vaccine within the past 2 weeks
  • You have a known allergy to any ingredient in the study vaccine
  • You have had a fever (38°C / 100°F or higher) in the 72 hours before vaccination
  • You have a history of immune deficiency conditions
  • You have had your spleen removed or have a non-functioning spleen
  • You have a history of cancer
  • You have a history of HIV infection
  • You have a primary (inherited) immune deficiency condition
  • You take immune-suppressing medications due to an organ transplant
  • You have an ongoing, uncontrolled long-term health condition such as heart failure, kidney failure, liver problems, or diabetes
  • You are currently hospitalised or have an acute illness at the time of screening
  • You have received a blood transfusion within the past 3 months
  • You are currently pregnant or breastfeeding
  • You are planning to become pregnant within 90 days after vaccination
  • You have taken part in another clinical trial within the past 30 days

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.

Contact this trial

Phone: +55 11 2661-8806

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 4
Registry
ClinicalTrials.gov
Start date
16 March 2026
Est. completion
30 December 2027

Where this trial is recruiting

🇧🇷 Brazil

Primary endpoints

Seroconversion Rate After Vaccination; Frequency and Intensity of Common Adverse Events

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov